Genmab (ADR)
Develops antibody medicines through partner royalties, co-commercialization, and a wholly owned oncology portfolio.
$33.25
After-hours close+0.03 (+0.09%)
At close$33.22(−2.58%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.36 | — | — |
| Aug 2026 | $0.37 | $0.54 | +45.9% |
| May 2026 | $0.15 | $0.15 | 0.0% |
| Feb 2026 | $0.46 | $0.05 | −89.1% |
| Nov 2025 | $0.48 | $0.65 | +35.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | $0.36 | — | — | $1.21B | — | — |
| Aug 6, 2026 | $0.37 | $0.54 | +45.9% | $1.12B | $1.16B | +3.5% |
| May 7, 2026 | $0.15 | $0.15 | 0.0% | $905.8M | $896.0M | −1.1% |
| Feb 17, 2026 | $0.46 | $0.05 | −89.1% | $1.07B | $1.06B | −0.8% |
| Nov 6, 2025 | $0.48 | $0.65 | +35.4% | $1.01B | $1.02B | +1.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 12, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 2, 2024 | ||||||
| Feb 14, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 10, 2023 | ||||||
| Feb 22, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 10, 2022 | ||||||
| May 11, 2022 | ||||||
| Feb 16, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 11, 2021 | ||||||
| May 5, 2021 | ||||||
| Feb 23, 2021 | ||||||
| Nov 4, 2020 | ||||||
| Aug 12, 2020 | ||||||
| May 6, 2020 | ||||||
| Feb 19, 2020 | ||||||
| Nov 6, 2019 | ||||||
| Aug 20, 2019 | ||||||
| Mar 31, 2019 | ||||||
| Dec 31, 2018 | ||||||
| Sep 30, 2018 | ||||||
| Jun 30, 2018 | ||||||
| Mar 31, 2018 | ||||||
| Dec 31, 2017 | ||||||
| Sep 30, 2017 | ||||||
| Jun 30, 2017 | ||||||
| Mar 31, 2017 | ||||||
| Dec 31, 2016 | ||||||
| Sep 30, 2016 | ||||||
| Jun 30, 2016 | ||||||
| Mar 31, 2016 | ||||||
| Dec 31, 2015 | ||||||
| Sep 30, 2015 | ||||||
| Jun 30, 2015 | ||||||